Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Global CRISPR Technology Research Report Report 2023-2027 Featuring Major Players - CRISPR Therapeutics, GenScript, Lonza Group, PerkinElmer, & Thermo Fisher Scientific

Research and Markets Logo

News provided by

Research and Markets

Jan 25, 2023, 13:50 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering.

A $9.2 Billion Market by 2027, from $3.3 Billion in 2022.

The current report provides detailed exposure to the CRISPR technology market. This report highlights the current and future market potential of CRISPR technology, along with a detailed analysis of the drivers, restraints, and challenges in the market.

The report also covers market projections for 2027, as well as the competitive environment and regulatory scenario. The report details the market share of CRISPR technology on applications and end users. The market is segmented into Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations (CROs) based on end users.

The market is categorized as Drug Development, Agriculture, Diagnostics, Clinical therapy, and Others based on Application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also discusses the impact of the COVID-19 pandemic on this market.

By geography, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year, and forecast for 2027.

Reasons for Doing This Study:

  • CRISPR offers lucrative potential for advanced pharmacological research, with impact spanning the entire preclinical drug discovery pipeline. This technology makes gene editing more tractable and precise and speeds up the process of identifying drug targets and generating realistic disease models. High costs associated with the innovation of new drugs are a risk for pharmaceutical companies and may limit the discovery of new therapeutics. New and advanced technologies like CRISPR remove these barriers, expanding the drug exploration process.
  • This report examines end users, applications, and markets in an effort to help companies and investors prioritize product opportunities and strategic movements. The report highlights key industry and market trends and quantifies the main market segments, allowing the reader to better understand the industry's structure and the changes occurring within it.
  • Favourable government regulations and funding that supports the application of CRISPR in various scientific fields across all regions create unique market opportunities. This report analyzes the trends and the impact on future growth and developmental opportunities of CRISPR applications in science.

Report Includes

  • 17 data tables and 37 additional tables
  • An up-to-date overview and analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
  • Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the market potential for CRISPR technology, industry growth drivers, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size and revenue forecast for the global CRISPR technology market in USD million terms, and corresponding market share analysis by application, end user, and region
  • Discussion of the major market dynamics, key shifts and regulations, industry specific challenges, and macroeconomic factors affecting the demand for CRISPR technology market over the coming years (2022-2027)
  • Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
  • A look at the recent technical breakthrough on the use of CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
  • Comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
  • Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
  • Insight into recent industry structure for CRISPR-Cas9 genome editing technology, competitive environment, clinical trials, ongoing research activities, and the COVID-19 impact on the marketplace

Company profiles of major players within the industry, including

  • CRISPR Therapeutics AG
  • GenScript
  • Lonza Group Ltd
  • PerkinElmer
  • Thermo Fisher Scientific Inc.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview
3.1 Crispr: Genetic Editing
3.2 Components of Crispr-Cas Systems
3.2.1 Sgrna
3.2.2 Cas9 Nucleases
3.3 How Crispr-Cas Works?
3.4 Advantage of the Crispr-Cas9 System
3.5 Popularity of Crispr Genome Editing
3.6 Pros of Genetic Editing
3.7 Crispr Development Phases
3.7.1 Discovery of Crispr
3.7.2 Discovery of Cas9 and Pam
3.7.3 Hypothesis: Adaptive Immunity
3.7.4 Adaptive Immunity
3.7.5 Spacer Sequences: Grnas
3.7.6 Crispr Acts on Dna Targets
3.7.7 Cas9 Cleaves Target Dna
3.7.8 Tracrrna for Cas9 Systems
3.7.9 Crispr Systems in Other Species
3.7.10 Cas9-Mediated Cleavage
3.7.11 Crispr-Cas9: Genome Editing
3.8 Market Potential
3.9 Regulatory Framework
3.9.1 U.S. Regulation and Oversight
3.9.2 Nih Guidelines
3.9.3 U.S. Fda
3.9.4 Regulatory Issues
3.9.5 Regulations of Human Germline Edits
3.9.6 Global Regulations
3.10 Porter's Five Forces Analysis of the Market for Crispr Technology
3.11 Scientific Publications
3.12 Patent Analysis
3.12.1 Overview of Crispr Technology Intellectual Property (Ip) and Licensing Structure
3.13 Future of Crispr
3.14 Market Drivers
3.14.1 Crispr Versus Chronic Disease
3.14.2 High Prevalence of Genetic Disorders
3.14.3 Government and Private Funding
3.14.4 Increasing Applications of Crispr
3.15 Market Restraints
3.15.1 Alternative Technologies
3.15.2 Off-Target Activity
3.16 Market Challenges
3.16.1 Patent Issues
3.16.2 Risks Associated With Crispr
3.16.3 R&D
3.16.4 Governmental Policies and Regulations
3.16.5 Bioethical Issues

Chapter 4 Industry Structure
4.1 Commercial Therapeutics
4.2 Correcting Genetic Errors
4.3 Microbes
4.4 Healthier Food

Chapter 5 Impact of Covid-19 on the Market for Crispr Technology
5.1 Overview

Chapter 6 Competitive Landscape
6.1 Overview
6.2 Competitive Scenario
6.3 Beam Therapeutics
6.4 Crispr Therapeutics
6.5 Editas Medicine
6.6 Intellia Therapeutics
6.7 Growth Strategies
6.7.1 Licensing and Agreements
6.7.2 Collaborations With Big Biopharmaceutical Companies
6.7.3 Mergers and Acquisitions

Chapter 7 Global Market for Crispr Technology by End-user
7.1 Market Overview
7.2 Market Share and Forecast
7.3 Biotechnology and Pharmaceutical Companies
7.4 Academics and Government Research Institutes
7.5 Contract Research Organizations

Chapter 8 Global Market for Crispr Technology by Application
8.1 Market Share and Forecast
8.2 Drug Development
8.3 Agriculture
8.4 Diagnostics
8.4.1 Infectious Diseases
8.4.2 Non-Infectious Diseases
8.5 Clinical Therapy
8.6 Others

Chapter 9 Global Market for Crispr Technology by Region
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Rest of Asia-Pacific
9.4 Rest of the World

Chapter 10 Company Profiles

  • Caribou Biosciences
  • Crispr Therapeutics AG
  • Danaher Corp.
  • Editas Medicine
  • Genscript
  • Hera Biolabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences Inc.
  • New England Biolabs Inc.
  • Origene Technologies
  • Perkinelmer
  • Precision Biosciences
  • Synthego
  • Thermo Fisher Scientific
  • Toolgen Inc.

For more information about this report visit https://www.researchandmarkets.com/r/izz1lm

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.